Connect with us

Health

Man paralyzed in diving mishap has medical miracle a year after AI-powered brain implant

Published

on

Man paralyzed in diving mishap has medical miracle a year after AI-powered brain implant

Join Fox News for access to this content

Plus special access to select articles and other premium content with your account – free of charge.

By entering your email and pushing continue, you are agreeing to Fox News’ Terms of Use and Privacy Policy, which includes our Notice of Financial Incentive.

Please enter a valid email address.

Having trouble? Click here.

A New York man who was left paralyzed after a diving accident is starting to regain movement a year after receiving an artificial intelligence-powered implant in his brain.

A year ago, Keith Thomas, 46, was only able to move his arms an inch. Today, after the groundbreaking procedure, he is able to extend his arm, grasp a cup and take a drink using only his thoughts and stimulation. 

Advertisement

He has also regained more sensation in his wrist and arm, allowing him to feel the fur of his family’s dog.

JOHNNY DEPP VISITS CHILDREN’S HOSPITAL DRESSED AS CAPTAIN JACK SPARROW IN ‘MAGICAL MOMENT’

In 2020, Thomas was living on Long Island and working as a trader on Wall Street when he experienced a diving accident that left him paralyzed from the chest down.

“I dove into a swimming pool at a friend’s house between the shallow and deep end,” he told Fox News Digital. “I hit the bottom and broke my neck. I blacked out, and I couldn’t move.”

Keith Thomas, right, who was left paralyzed after a diving accident, is starting to regain movement a year after receiving an AI-powered implant in his brain. Thomas is also pictured left, front, with his care team.  (Feinstein Institutes for Medical Research at Northwell Health)

Advertisement

Thomas recalls getting loaded into a helicopter that took him to the hospital for the start of his long recovery. 

“It was during COVID, so it was extremely difficult and isolating.”

A ‘groundbreaking’ procedure

A year ago, Thomas could only move his arms an inch. But in 2023, he underwent a grueling 15-hour surgery, during which the first AI-powered double neural bypass implant was placed in his brain at Feinstein Institutes for Medical Research at Northwell Health in New York.

“This groundbreaking clinical trial marks the first time the brain, body and spinal cord have been electronically linked in a paralyzed human to restore lasting movement and sensation,” Chad Bouton, the study’s principal investigator and professor in the Institute of Bioelectronic Medicine at The Feinstein Institutes, told Fox News Digital.

AI FAST-TRACKS DEMENTIA DIAGNOSES BY TAPPING INTO ‘HIDDEN INFORMATION’ IN BRAIN WAVES

Advertisement

The surgical team, led by neurosurgeon Dr. Ashesh Mehta at Northwell Health, implanted five microchips in Thomas’ brain — two in the region responsible for movement and three that control the sensation of touch.

“These microchips connect to two ports implanted in his skull, which are linked to a powerful computer running custom AI that we developed to read Keith’s brainwaves and determine when he wants to move his hand,” Bouton said.

Keith Thomas with care team

Thomas, who lives with paralysis, poses with the research team at Northwell Health’s Feinstein Institutes for Medical Research — which worked with him for months to restore lasting movement and feeling in his arm and hand. (Northwell Health’s The Feinstein Institutes for Medical Research)

Based on thoughts, the device – called a “double neural bypass” – reroutes signals around his injury between his brain and body, the doctor detailed. 

“The double neural bypass technology also stimulates his muscles, brain and spinal cord, all based on his brain patterns, and promotes lasting recovery of movement and sensation.”

“Keith’s brain, body and spinal cord are re-learning how to work together once again.”

Advertisement

The surgery required Thomas to be awake at one point to ensure the precise placement of the microchips in his brain. 

“It was a little fuzzy, but I remember hearing someone ask me if I felt something, and I felt a tingle in certain part of my hand,” Thomas recalled.

Three major milestones

After the surgery, he’s regularly returned to the lab at Feinstein Institutes, where the team is monitoring his progress and conducting a clinical trial of the results.

“Once I was out of surgery and saw the improvements during lab sessions, it was incredible,” he said. “I was speechless.”

Keith Thomas brain implant

Thomas had five tiny microchips implanted in his brain, forming a critical portion of a first-of-its-kind “double neural bypass.” The technology uses artificial intelligence to decode and translate his thoughts into action. (Northwell Health’s The Feinstein Institutes for Medical Research)

Thomas has reached three major milestones, exceeding the team’s expectations. 

Advertisement

“First, only a few months after surgery, Keith felt the touch of his sister’s hand for the first time in three years since his accident,” Bouton said. “There was not a dry eye in the lab at that moment.”

Second, Thomas doubled his arm strength over the course of the study, which is not usually possible three years after a major spinal cord injury, the doctor said.

SPINAL CORD TREATMENT RESTORES FUNCTION FOR PARALYZED PATIENTS IN STUDY: ‘NEW HOPE’

“Lastly, with his regained arm strength and sensation, Keith was recently able to feel and lift a cup of tea to his mouth, and take a drink, without any help and using his thoughts alone,” Bouton shared.

“This was an amazing moment and what we’ve been working for during these past few years.”

Advertisement
Keith Thomas with sister

Keith Thomas is able to feel his sister hold his hand for the first time since a diving accident in 2020 left him paralyzed from the chest down. (Northwell Health’s The Feinstein Institutes for Medical Research)

Thomas has also regained sensation in areas that are below his injury level, such as his wrist, even outside the lab.

“This suggests that Keith’s brain, body and spinal cord are re-learning how to work together once again, and some connections are being strengthened,” Bouton said.

      

Thomas described his own progress as “mind-boggling.”

“Every day, I feel like we are accomplishing more and more.”

Advertisement

Looking ahead

The goal is for Thomas to continue to gain more movement and sensation outside the lab, and he hopes to one day drive his own motorized wheelchair without assistance.

Keith Thomas

After joining a clinical trial at Northwell Health’s Feinstein Institutes for Medical Research that uses brain implants and artificial intelligence to reconnect his brain with healthy parts of his spinal cord, Thomas has continuously improved, restoring movement and feeling in his arm and hand. (Northwell Health’s The Feinstein Institutes for Medical Research)

Added Thomas, “I want to continue making progress to live a more independent life – and if I can inspire others to sign up for a clinical trial or help someone else through this trial, that’s all I want.”

Bouton said he and the team are “optimistic” that Thomas will continue to improve over time as he uses the double neural bypass technology. 

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“We are continuing to monitor his progress in terms of sensation and movement recovery,” he said. “Our team has also received approval to expand our clinical trial, and we are actively seeking new participants.”

Advertisement
Surgeons at Northwell Health’s The Feinstein Institutes for Medical Research

The Feinstein Institutes for Medical Research’s Prof. Bouton (left) and Dr. Ashesh Mehta led teams of doctors and scientists to implant brain electrodes, which restored lasting movement and sensation in a man living with paralysis. (Northwell Health’s The Feinstein Institutes for Medical Research)

Bouton said he believes that AI has significant potential to improve outcomes for paralyzed patients.

“AI is already changing how medicine is being practiced today, but we believe our work in combining AI with brain-computer interface technology will revolutionize the treatment of paralysis and many other conditions in the future,” he said.

For more Health articles, visit www.foxnews.com/health

“Our goal is to one day utilize this technology to empower individuals with paralysis to regain more function and live more independent lives.”

Advertisement
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Health

Paxlovid Improved Long Covid Symptoms in Some Patients, Researchers Report

Published

on

Paxlovid Improved Long Covid Symptoms in Some Patients, Researchers Report

Can Paxlovid treat long Covid? A new report suggests it might help some patients, but which patients might benefit remains unclear.

The report, published Monday in the journal Communications Medicine, describes the cases of 13 long Covid patients who took extended courses of the antiviral drug. Results were decidedly mixed: Nine patients reported some improvement, but only five said it lasted. Four reported no improvement at all.

Perhaps more than anything, the report underscores that nearly five years after the pandemic began, there is still little known about what can help the millions of people with long Covid. While some people improve on their own or with various therapies and medications, no treatment has yet been shown to be widely successful.

“People with long Covid are eager for treatments that can help,” said Alison Cohen, an epidemiologist at the University of California, San Francisco, who is an author of the new report and has long Covid herself. “There’s been a lot of research, but it continues to be slow going.”

Paxlovid, made by Pfizer, is considered a tantalizing prospect because it can prevent severe illness during active Covid infections and because patients who take the five-day course during the infection have been less likely to develop long Covid later.

Advertisement

In addition, a theory that some long Covid cases may be caused by remnants of virus in the body suggests that an antiviral like Paxlovid might vanquish those symptoms by extinguishing lingering virus.

Last year, the first randomized trial of Paxlovid for long Covid showed no benefit. Conducted at Stanford, it involved 155 patients who took the drug or a placebo for 15 days. While taking Paxlovid for that long was found to be safe, it didn’t help patients much: Ten weeks later, the placebo and Paxlovid groups showed no significant difference in severity of long Covid symptoms.

Dr. Upinder Singh, an infectious disease specialist and a leader of that trial, said its results and the new report primarily generated “more questions to answer”: Could Paxlovid help if taken for longer than 15 days or paired with other medications? Does its effect vary by types of symptoms or by when symptoms started?

“It’s very possible that within long Covid, there’s different disease types,” said Dr. Singh, now head of internal medicine at the University of Iowa. Maybe Paxlovid or other antivirals would help patients who could be clearly determined to have lingering virus in their bodies, she said.

Akiko Iwasaki, an immunologist at Yale University, said scientists shouldn’t “throw in the towel” on the possibility of antivirals for long Covid.

Advertisement

“If you look in the aggregate, you don’t see a difference between the placebo group, but these case reports demonstrate there are people who truly benefit, so we need to home in on those people,” said Dr. Iwasaki, who is leading another randomized trial of Paxlovid, the results of which have yet to be published.

She said important next steps would be identifying biological markers in people whose long Covid symptoms improved with Paxlovid and seeing whether other antivirals help different patients.

The new report was not a clinical trial, but a collection of self-reports from 13 long Covid patients around the country who had tried extended courses of Paxlovid. It is the first published case series of such patients, according to the authors, who include Dr. Michael Peluso, an infectious disease physician at U.C.S.F., and members of the Patient-Led Research Collaborative, a group of researchers who also have long Covid.

The experiences of the patients were too varied to yield a consistent trajectory, but the variety may provide clues for larger studies, the authors said.

The patients, ranging in age from 25 to 55, were infected between March 2020 and December 2022. They experienced one or more of a range of symptoms, including fatigue; gastrointestinal problems; cognitive problems like brain fog; muscle pain; irregular heart rate; and a condition called post-exertional malaise, in which physical or mental exertion causes setbacks.

Advertisement

As with the Stanford trial, most patients in the new report had been vaccinated by the time they took Paxlovid. Their Paxlovid courses ranged from 7.5 days to 30 days. Most tried it to find relief from their persistent long-Covid symptoms; two patients with long Covid received extended courses of Paxlovid when they were reinfected with the virus.

Most patients were also taking other medications or supplements, making it difficult to determine the drug’s specific effect, Dr. Cohen said. Still, some said Paxlovid helped them significantly.

Kate Leslie, 46, a social worker in Boulder, Colo., said she was healthy and athletic before her coronavirus infection in March 2022. Six weeks later, she said, she felt as if she’d had a concussion, struggling to think clearly and find words.

She developed postural orthostatic tachycardia syndrome, with symptoms including erratic heart rate and blood pressure and occasional fainting. A longtime Ultimate Frisbee player and coach, she began experiencing profound fatigue and could barely lift her arms.

“It was like concrete blocks are on your body,” she said. “I couldn’t get out of bed. My husband had to wash my hair and dry it and dress me.”

Advertisement

After an antiviral she was prescribed for a flu infection, Tamiflu, ended up easing some of her long Covid symptoms, Ms. Leslie wondered whether Covid-related antivirals might help even more, she said. In February 2023, she found a doctor to prescribe a 15-day course of Paxlovid.

Afterward, “I could feel my body getting restabilized,” she said, adding, “I started to get my energy back.”

About six months later, she obtained another 15-day course, which helped again, she said. She estimates she can now function at about 85 percent of her pre-Covid level.

Ms. Leslie said, however, that a couple of her medical issues worsened after Paxlovid, including an immune system condition that has caused allergies. Three other patients also reported bothersome issues after taking Paxlovid, including tingling and gastrointestinal discomfort.

Among those who didn’t perceive any benefit from the drug was Julia Moore Vogel. Dr. Vogel, 39, a senior program director at Scripps Research, was a long-distance runner before being infected with the coronavirus in July 2020. Now she uses a wheelchair and is largely housebound, she said.

Advertisement

She and her daughter recently moved across the country, from California, to live with her parents in Schaghticoke, N.Y. “I got to the point where we were like, I either need to stop working or we need more help at home,” she said.

Dr. Vogel, whose symptoms include fatigue, post-exertional malaise and migraines, took a 10-day course of Paxlovid in April 2023. “It just had no impact for me at all,” she said.

These days, she manages by carefully budgeting her energy, trying to leave the house no more than once a week. Migraine medications provided some relief, she said, but other than that, “I’ve tried many things, and basically nothing has really helped me improve.”

Dr. Cohen said the report strengthens the theory that long Covid has many different causes and treatments.

“A really important question is who may benefit from taking an extended course of Paxlovid and why,” she said, “and if it benefits some symptoms, which symptoms does it benefit?”

Advertisement
Continue Reading

Health

AI detects ovarian cancer better than human experts in new study

Published

on

AI detects ovarian cancer better than human experts in new study

Join Fox News for access to this content

Plus special access to select articles and other premium content with your account – free of charge.

By entering your email and pushing continue, you are agreeing to Fox News’ Terms of Use and Privacy Policy, which includes our Notice of Financial Incentive.

Please enter a valid email address.

Having trouble? Click here.

For the nearly 20,000 women in the U.S. who receive an ovarian cancer diagnosis each year, artificial intelligence is emerging as a potentially life-saving tool.

In a new study led by researchers at Karolinska Institutet in Sweden, AI models did a better job of detecting ovarian cancer than human doctors. 

Advertisement

The research, which was published in Nature Medicine, tested an AI model’s ability to distinguish between benign and malignant lesions on the ovaries, according to a press release.

WHAT IS ARTIFICIAL INTELLIGENCE?

The AI model was trained on more than 17,000 ultrasound images from 3,652 patients across 20 hospitals in eight countries, the release stated.

“High-quality diagnostics can become more accessible, particularly in regions with limited access to experienced examiners,” said a study author. (iStock)

The AI model achieved an accuracy rate of 86% for detecting ovarian cancer, compared to 82% for human experts and 77% for those with less expertise.

Advertisement

“I was surprised that the AI models outperformed all 33 of the expert examiners,” study author Elisabeth Epstein, a professor at the Department of Clinical Science and Education at Karolinska Institutet, told Fox News Digital.

PARENTS TRUST AI FOR MEDICAL ADVICE MORE THAN DOCTORS, RESEARCHERS FIND

Ovarian tumors are common and “often detected by chance,” according to Epstein. 

“Our study demonstrates that AI-driven diagnostic support can significantly improve ovarian cancer diagnosis by enhancing triage efficiency, reducing diagnostic errors and addressing the shortage of expert examiners,” she said in a statement to Fox News Digital. 

AI medical concept

The AI model achieved an accuracy rate of 86% for detecting ovarian cancer, compared to 82% for human experts and 77% for those with less expertise. (iStock)

“High-quality diagnostics can become more accessible, particularly in regions with limited access to experienced examiners,” Epstein went on. 

Advertisement

“This will help reduce waiting times, avoid unnecessary interventions and facilitate earlier cancer detection, ultimately improving patient outcomes and ensuring more accurate diagnoses.”

AI could also reduce the need for referrals as well as the chances of misdiagnosis, the researchers noted.

“I was surprised that the AI models outperformed all 33 of the expert examiners.”

Dr. Brian Slomovitz, director of gynecologic oncology and co-chair of the Cancer Research Committee at Mount Sinai Medical Center in Florida, noted that screening and early detection of ovarian cancer is the “holy grail” to reduce deaths from this disease.

OVARIAN CANCER TREATMENT ON FAST TRACK FOR FDA APPROVAL AS CHEMO ALTERNATIVES EMERGE: ‘WE’RE MAKING PROGRESS’

Advertisement

“This large retrospective trial clearly demonstrates that there may be a role in incorporating AI-driven support to better interpret ultrasound findings in patients with a pelvic mass,” Slomovitz, who was not involved in this particular study, told Fox News Digital. 

“This, by itself, increases the accuracy of the radiologic findings by both decreasing the false positive rate (leading to unnecessary surgeries) and decreasing the false negative rate (missing cases of cancer).”

Ovarian cancer scans

Screening and early detection of ovarian cancer is the “holy grail” to reduce deaths from this disease, one oncologist noted. (iStock)

There are other ways to evaluate ovarian cancer patients beyond radiology scans, the doctor noted.

“Menopausal status, presence or absence of symptoms, and blood test results are some other factors used to determine which patients may or may not need surgery,” Slomovitz said. “It would be great if these factors could be incorporated into the AI modeling.”

OVARIAN CANCER SIGNS, SYMPTOMS, DIAGNOSIS AND TREATMENT OPTIONS

Advertisement

In addition to showing improved accuracy of ultrasound analysis, the AI technology will need to demonstrate a survival benefit in order to gain widespread use, he added.

“I am optimistic that artificial intelligence will be a part of the armamentarium used to improve the care we offer to our patients.”

AI health care

“I am optimistic that artificial intelligence will be a part of the armamentarium used to improve the care we offer to our patients,” an oncologist said. (iStock)

Dr. Harvey Castro, a Dallas, Texas-based board-certified emergency medicine physician and national speaker on AI in health care, agreed that the tech has the potential to improve cancer diagnostics, but cautioned that limitations remain.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“The AI relies on diverse, high-quality data, and bias could limit effectiveness,” he told Fox News Digital.

Advertisement

“It’s also not fully validated for routine clinical use, and transparency and regulatory concerns remain unresolved.”

Castro reiterated that additional research is needed to determine how well AI adapts to real-world settings, the long-term impact on health care costs and outcomes, and whether the tech will be able to handle diverse populations and different clinical environments.

For more Health articles, visit www.foxnews.com/health

The researchers also acknowledged the potential limitations of the study.

“It is not a prospective study, so additional data is needed to know how it would perform in a real clinical setting,” Epstein told Fox News Digital. 

Advertisement

OVARIAN CANCER COULD BE DETECTED EARLY WITH A NEW BLOOD TEST, STUDY FINDS

The team is planning to soon begin clinical studies at Stockholm South Hospital in Sweden, she added.

“It is still the physician who remains responsible for the patient’s diagnosis and treatment.”

Epstein noted that AI should only be used as a diagnostic support and not a replacement for human physicians. 

“It is still the physician who remains responsible for the patient’s diagnosis and treatment,” she stated. 

Advertisement

      

The Karolinska Institutet research team collaborated with the KTH Royal Institute of Technology. Funding was provided by the Swedish Research Council, the Swedish Cancer Society, the Stockholm Regional Council, the Cancer Research Funds of Radiumhemmet and the Wallenberg AI, Autonomous Systems and Software Program (WASP), according to the release.

Continue Reading

Health

Ozempic ‘microdosing’ is the new weight-loss trend: Should you try it?

Published

on

Ozempic ‘microdosing’ is the new weight-loss trend: Should you try it?

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic.

With approximately 70% of American adults meeting the criteria for being obese or overweight, more people are turning to weight loss medications to help them shed pounds.

Ozempic is approved for type 2 diabetes, while its counterpart, Wegovy, is approved for treating obesity. Both are made by Novo Nordisk.

‘YO-YO’ WEIGHT LOSS OCCURS BECAUSE OF THIS SURPRISING REASON

Eli Lilly also offers a diabetes medication, Mounjaro, as well as a version for weight loss, Zepbound.

Advertisement

In a new trend, some people are using smaller daily “microdoses” of Ozempic, doctors report.  (iStock)

“Ozempic is the only version among the weekly injectables — Ozempic, Wegovy, Zepbound and Mounjaro — that has the option to ‘hack’ the pen for a smaller dose,” Dr. Alexandra Sowa, an obesity medicine specialist and founder of SoWell in New York, told Fox News Digital.

She is also the author of the book “The Ozempic Revolution” that is set to be released on Jan. 7.

Fox News Digital spoke to the experts to get the skinny on this latest trend.

What is microdosing?

Microdosing Ozempic refers to using smaller amounts compared to the standard therapeutic doses that are traditionally prescribed for managing type 2 diabetes and aiding weight loss, experts say. 

Advertisement

This practice is not approved by the U.S. Food and Drug Administration (FDA).

IS EATING ONCE A DAY A GOOD IDEA? EXPERTS SHARE VARYING OPINIONS ON THE ‘OMAD DIET’

“Health care clinicians do not typically recommend this approach, as the standard dosing regimen is based on clinical trials determining the most effective and safe amount for these conditions,” noted Dr. Fatima Cody Stanford, obesity medicine physician at Massachusetts General Hospital and Harvard Medical School.

There are no established guidelines for microdosing – although there are reports on social media of using 10 to 100 times lower than standard prescriptions, added Dr. Christopher McGowan, a gastroenterologist and obesity specialist who runs True You Weight Loss in Cary, North Carolina.

“Health care clinicians do not typically recommend this approach.”

Advertisement

Some people get confused by the terminology, the doctors noted.

“I think there’s a little bit of a misconception, as some people say ‘I’m microdosing’ when they’re just on the starting doses or don’t go all the way up in the escalation titration dosing of the medication,” Sowa said.

Benefits of microdosing

The primary reason for microdosing is to reduce costs, according to McGowan.

For example, he said, a patient might think that if a full prescription costs over $250 per week, they may be able to achieve some benefit with just $25 worth of the medication.

Seniors Ozempic split

With approximately 70% of American adults meeting the criteria for being obese or overweight, more people are turning to weight loss medications to help them shed pounds. (iStock)

The average monthly retail price of Ozempic ranges from $1,000 or more without insurance, per GoodRx.

Advertisement

People may also pursue microdosing to reduce the incidence or severity of side effects such as nausea, vomiting or stomach discomfort, according to Stanford.

“Some individuals might start with microdoses to gradually acclimate their body to the medication, potentially easing into the full therapeutic dose over time,” she said.

CHEAP OZEMPIC KNOCK-OFFS HAVE RISEN IN POPULARITY

Any potential benefit of the medication, however, will likely wane proportionally with lower doses, experts noted.

Individuals may also microdose due to supply challenges, according to Dr. Amy Rothberg, clinical professor of medicine in the Division of Metabolism, Endocrinology & Diabetes at the University of Michigan. 

Advertisement
Insulin injection

“Some individuals might start with microdoses to gradually acclimate their body to the medication, potentially easing into the full therapeutic dose over time.” (iStock)

“Some feel they may derive a benefit from microdosing by being able to extend their supply and may perceive an effect,” Rothberg, who is also the medical director of Rewind, a lifestyle program for type 2 diabetes patients, told Fox News Digital. “As we know, the placebo effect may have a strong impact.”

Potential risks of the practice 

The most likely risk of microdosing is a lack of effectiveness, McGowan noted.

“Microdosing Ozempic or other [weight-loss] medications is entirely off-label and unproven, with no supporting clinical studies,” he cautioned.

OZEMPIC COULD HELP REDUCE ALZHEIMER’S RISK FOR SOME, STUDY SUGGESTS: ‘SHIFTING THE PARADIGM’

Stanford also warned that smaller doses may not provide adequate blood sugar management, leading to uncontrolled diabetes and associated complications.

Advertisement

It can also lead to suboptimal weight loss and unpredictable results, as well as the potential for misuse, she added.

OZEMPIC PUSH FOR SENIORS? SOME DOCTORS SAY MORE PEOPLE AGE 65 AND OVER SHOULD BE ON IT

People who microdose often use a “compounded” version of the medication, which the FDA does not regulate.

“This introduces risks such as contamination, inconsistent formulations and uncertainty about the actual strength of the product being injected,” McGowan stated.

Obesity

Without changes to diet and physical activity patterns, the long-term benefits will disappear once the drug is stopped, one doctor noted. (iStock)

Additionally, these compounded versions are usually dispensed in vials, which requires a syringe to draw it up, in contrast to the FDA-approved versions that are simpler to use.

Advertisement

Using the compounded versions through vials runs the risk of drawing up too much medication — so instead of microdosing, it’s possible to macrodose, Sowa warned. 

Medical supervision is key 

Some providers are still comfortable offering microdosing for select patients with one caveat — that people should always consult a health care clinician before altering their medication regimen. 

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“As long as it is being dispensed and monitored by a physician, I don’t see how anybody is going to overdose, especially when we are giving such small amounts,” Dr. Suzanne A. Trott, a double board-certified plastic and general surgeon in Beverly Hills, told Fox News Digital.

“I have seen a lot of patients who are given metformin for weight loss — I don’t see how this is any different,” said Trott, who runs her own microdosing clinic.

Advertisement

Trott pointed out that there are many “off-label” practices offered to patients.

Botox and fillers are not even FDA-approved for most of the places we use them,” she noted.

“Some individuals might start with microdoses to gradually acclimate their body to the medication.”

Experts agree that sustained weight loss will not occur with medication alone.

Advertisement

“I think people find that it’s easier to take a drug, but neglect concomitant behavioral changes,” Rothberg said.

For more Health articles, visit www.foxnews.com/health

In the absence of changes to diet and physical activity patterns, the long-term benefits will disappear once the drug is stopped, she noted.

Trott also recommends maintaining consistent exercise, strength training, hydration and high protein intake to maintain muscle mass.

Fox News Digital reached out to Novo Nordisk, the maker of Ozempic, for comment.

Advertisement

Continue Reading

Trending